NRx Pharmaceuticals Q4 Earnings Call Highlights

• 5 Biotech stocks tapping into unmet intelligence wellness attraction needs

NRx Pharmaceuticals (NASDAQ:NRXP) executives utilized the company’s fourth-quarter 2025 results telephone to outline what they described arsenic a “pivotal and transformative” year, highlighting advancing regulatory pathways for preservative-free ketamine and an investigational ketamine product, arsenic good arsenic an expanded strategy for its NRX-101 programme tied to transcranial magnetic stimulation (TMS). Management besides pointed to aboriginal gross procreation from its HOPE Therapeutics session subsidiary and a year-over-year diminution successful operating expenses.

Founder, Chairman, and CEO Dr. Jonathan Javitt said the institution is pursuing “three imaginable cause approvals” successful the adjacent term, portion gathering retired HOPE Therapeutics’ session network. He added that HOPE clinics are “demonstrating EBITDA affirmative gross growth,” and argued that, fixed the company’s “low currency burn,” occurrence successful immoderate 1 of its large initiatives could enactment a determination toward pro forma profitability by year-end. Dr. Javitt noted the company’s Form 10-K reflects lone a archetypal 4th of objective operations for HOPE (the 4th fourth of 2025).

→ Planet Labs: The Satellite Stock That Keeps Shooting to the Moon

• Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

NRx ended 2025 with $7.8 cardinal successful currency connected hand, eliminated each convertible indebtedness from its equilibrium sheet, and expects—based connected increasing session revenues and its at-the-market (ATM) activity—to person capable resources to money operations done astatine slightest the extremity of 2026, according to management.

The company’s abbreviated caller cause exertion (ANDA) for preservative-free ketamine, referred to arsenic KETAFREE pending a last FDA commercialized sanction decision, remains a cardinal near-term catalyst. Dr. Javitt said FDA approved NRx’s suitability petition for the projected spot successful August 2025, and the institution filed its ANDA successful September 2025. In November, NRx received notification that FDA identified nary important deficiencies and agreed to reappraisal the file.

→ Trash to Treasure: 3 Waste Removal Stocks to Minimize Volatility

Last week, the institution was notified by FDA of a preliminary determination of bioequivalence to the notation branded cause Ketalar, which Dr. Javitt characterized arsenic a cardinal measurement successful generic cause review. He added that room-temperature stableness information enactment “at slightest 3 years” of stability, and that NRx has manufactured 3 registration batches successful anticipation of a summertime 2026 approval.